Here, we describe UCART2, a novel CD2-targeting allogeneic CAR-T therapy in which the biallelic deletion of CD2 and TRAC prevents fratricide and life-threatening GvHD while effectively killing CD2+ primary human T-ALL and CD2 + T-ALL and CTCL cell lines in vitro and in vivo. Here, CD2 is linked to acute lymphoblastic leukemia.